Registration successful.
Account activated – Pending validation
Your account has been activated successfully, but we still need to validate you as a UK healthcare professional. We’ll send you an email with the result. Please note this could take up to 10 days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website.
Anoro Ellipta is the only LAMA/LABA with head-to-head data vs. a LAMA1,2,5,6 and vs. two LAMA/LABAs3,4
In a post hoc, pooled analysis of 3 RCTs at 24 weeks in patients not on maintenance therapy (for ≥30 days before screening):1,2
In two (out of three) individual 24-week RCTs in COPD patients not on maintenance therapy at the study screening visit:5,6
Anoro Ellipta significantly reduced rescue medication use vs. tiotropium HandiHaler5,6
In an 8-week open-label crossover study in patients not on maintenance therapy (for ≥2 weeks prior to randomisation):3
Find out more about Anoro Ellipta's head-to-head data:
Start with a LAMA/LABA
When your patients with COPD struggle with breathlessness, your choice of first-line maintenance therapy could make a difference.
Are all LAMA/LABAs the same?
Anoro Ellipta has head-to-head data
vs. Spiolto Respimat3 (a LAMA/LABA) and
vs. Bevespi Aerosphere4 (a LAMA/LABA).
References
- Maleki-Yazdi M et al. Adv Ther 2016; 33:2188–2199
- GSK data on file RF/UCV/0112/15
- Feldman G.J et al. Adv Ther 2017; 34:2518–2533
- Maltais F et al. Adv Ther 2019; 36(9):2434-2449
- Maleki-Yazdi MR et al. Respir Med 2014;108:1752–1760
- Decramer M et al. Lancet Respir Med 2014;2:472–486.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to GlaxoSmithKline UK on 0800 221 441.
© 2021 GSK group of companies or its licensor.
ANORO was developed in collaboration with INNOVIVA.
Trademarks are owned by or licensed to the GSK group of companies.
PM-GB-UCV-WCNT-200036 May 2021
